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Nasopharyngeal carcinoma is an Epstein-Barr virus (EBV)-associated tumor. Viruses 
that are associated with malignant transformation have evolved unique mechanisms to 
interfere with this interaction to evade antiviral T-cell responses. EBV exploits many 
immune evasive strategies to successfully establish a latent infection in B cells. CD8+ 
T-cell responses to LMP-1 are generally very low and rarely detected in healthy virus 
carriers. Activation of the NF-kB pathway by EBV–LMP-1 leads to an up-regulation of 
the MHC class I antigen–processing pathway. Paradoxically, LMP-1 itself induces a 
subdominant CD8+ T-cell response and appears to have evolved to avoid immune 
recognition. An expression of LMP-1 in human cells enhanced the trans-presentation of 
CD8+ T-cell epitopes, however, cis-presentation of LMP-1–derived epitopes was 
severely impaired. Deletion of the first transmembrane domain of LMP-1, which 
prevented self-aggregation, significantly enhanced cis-presentation of T-cell epitopes 
from this protein, whereas it lost its ability to up-regulate trans-presentation. These 
results delineate a novel mechanism of immune evasion, which renders a virally 




Epstein-Barr virus (EBV) exploits many immune evasive strategies to 
successfully establish a latent infection in B cells and epithelial malignant tumors such 
as nasopharyngeal carcinoma (NPC). Analysis of the role of individual EBV latent 
antigens in the regulation of antigen-processing genes indicated that latent membrane 
protein-1 (LMP-1) was sufficient to up-regulate expression of transporters associated 
with antigen processing and trans-presentation of MHC class I–restricted epitopes in B 
cells1). Subsequent studies demonstrated that the immunomodulatory effects of LMP-1 
are mediated through C-terminal activator regions (CTAR1 and CTAR2), which are 
involved in the induction of the nuclear factor–κB (NF-κB). At the same time, LMP-1 
promotes invasion and metastasis through these intracellular activation domains2-4).  
Paradoxically, the population of CD8+ T-cell that responses to LMP-1 is generally very 
low and rarely detected in healthy virus carriers, suggesting that LMP-1 may limit its 
cis-presentation through the MHC class I pathway. We have delineated a mechanism by 
which LMP-1 limits its self-presentation without compromising its ability to modulate 
trans-presentation of CD8+ T-cell epitope5, 6) 
To assess trans-presentation of LMP-1, we transfected multiple LMP-1 sequences to 
epithelial cell lines. Although all LMP-1 variants up-regulated the expression of MHC 
class I on a human epithelial cell line, C33A, considerable activation of LMP-1-specific 
T cells was only evident after incubation with peptide-sensitized cells. In contrast, 
LMP-1 expression in C33A cells enhanced trans-presentation of CD8+ T-cell epitopes 
from another EBV-encoded membrane protein, LMP-2A. Collectively, these results 
suggested that, despite its capacity to up-regulate trans-presentation via the MHC class I 
pathway, LMP-1 limits its self-presentation to CD8+ T cells.  
Much of the data presented are based on either stable or transient expression of LMP-1. 
To confirm these observations, we assessed endogenous presentation of LMP-1 epitopes 
in EBV-transformed LCLs. Although activation of LMP-2A specific T cells was evident 
after incubation with HLA-matched LCLs, very low levels of activation of T cells 
specific for multiple LMP-1–encoded peptide epitopes was observed. Activation of 
LMP-1–specific T cells could be detected after incubation with peptide-sensitized LCLs.  
To investigate the mechanism for this immune evasion, we tested a series of LMP-1 
expression vectors with mutations in the CTAR1 and/or CTAR2 domain; and a deletion 
mutant commencing at the second methionine of LMP-1 (Δ1-43LMP-1-GFP), which 
removes the first trans-membrane domain. This domain has been shown to have 
immunomodulatory effect, andΔ1-43LMP-1 has been used for expanding 
LMP-1-specific T cells. Although mutations within the CTAR domains had no impact 
on the presentation of LMP-1 epitopes, deletion of the first trans-membrane domain 
enhanced endogenous presentation of HLA class I–restricted epitopes. Consistent with 
previous studies, intracellular localization analysis using fluorescent microscopy 
revealed that, although full-length LMP-1 and its CTAR mutants formed large 
aggregates in the perinuclear region, Δ1-43LMP-1-GFP lost its ability to aggregate. This 
enhanced presentation was not the result of increased expression ofΔ1-43LMP-1-GFP 
compared with full-length LMP-1. These observations indicate that, although the NF-κB 
signaling domains had no impact on cis-presentation of LMP-1 epitopes, aggregation of 
this protein (a critical requirement for trans-presentation) limits its accessibility to the 
MHC class I processing machinery.  
The data presented in this meeting indicate that, in addition to constraining its 
cis-presentation through aggregation, epitopes encoded within LMP-1 protein are most 
probably destroyed by cellular proteasomes, providing a dual strategy by which LMP-1 
limits self-presentation to CD8+ T cells7).  
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